XXXX : clinical evaluation in severe @entity364 .

@entity1 @entity697 @entity295 @entity55 @entity298 @entity3102 @entity4034 @entity326 @entity4895 @entity8304 @entity7409 @entity5132 @entity281 @entity364 @entity32269 @entity3225 @entity293
@entity3102 , a new @entity8304 -derivative antifungal agent, has been studied in sixteen @entity1 with @entity364 . Seven @entity1 had deep localized infections (three cases with @entity55 and one case each with @entity293 , @entity4034 , @entity3225 and @entity298 ); three @entity1 suffered from granulomatous or @entity697 and six @entity1 had @entity364 . All @entity1 suffered from severe underlying diseases and/or predisposing factors such as antibiotic treatment, immunosuppressive therapy or indwelling catheters. @entity5132 was isolated in 13 cases, @entity7409 ( @entity295 ), Aspergillus ( @entity32269 ) and Mucor ( @entity55 ) in the other three cases. @entity3102 was administered orally at daily dosages of 400-800 mg; @entity4895 was associated in four cases. Out of the ten @entity1 with localized infections, seven were cured and three improved. Two of the six septic @entity1 were cured, one improved who subsequently died from Pseudomonas @entity326 and three @entity1 showed no improvement. Two relapses were recorded, both followed by further eradication. The tolerance of the drug was always excellent. @entity3102 proved a very effective and well-tolerated drug in @entity281 , caused by opportunistic fungi in high-risk @entity1 .
